Alectinib

Generic name: Alectinib
Brand names: Alecensa
Dosage form: oral capsules
Drug class: Multikinase inhibitors

Usage of Alectinib

Alectinib is a type of cancer medication used to treat non-small cell lung cancer (NSCLC) in people who have an error in their anaplastic lymphoma kinase (ALK) gene. This error is found in about 5 percent of people with NSCLC.

The defect in the ALK gene causes it to fuse with other genes, which causes cells to grow out of control and leads to ALK-positive cancer.

Alectinib works by blocking the ALK receptor, which helps to stop or slow the spread of cancer. Alectinib is a ALK tyrosine kinase inhibitor.

Alectinib was approved by the US Food and Drug Administration (FDA) in 2015.

Alectinib side effects

Alectinib may cause serious side effects, including:

  • See "Important information"

    • The most common side effects of alectinib include:

  • tiredness
  • constipation
  • swelling in your hands, feet, ankles, face and eyelids
  • muscle pain, tenderness, and weakness (myalgia). See "Important information"
  • anemia

    • These are not all of the possible side effects of alectinib. For more information, ask your healthcare provider or pharmacist.

    Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

    Before taking Alectinib

    Tell your doctor if you are pregnant or plan to become pregnant. Alectinib can harm your unborn baby. Tell your healthcare provider right away if you become pregnant during treatment with alectinib or think you may be pregnant.

    Females who are able to become pregnant should use effective birth control during treatment with alectinib and for 1 week after the final dose of alectinib.

    Males who have female partners that are able to become pregnant should use effective birth control during treatment with alectinib and for 3 months after the final dose of alectinib.

    Tell your doctor if you are breastfeeding or plan to breastfeed. It is not known if alectinib passes into your breast milk. Do not breastfeed during treatment with alectinib and for 1 week after the final dose of alectinib. Talk to your healthcare provider about the best way to feed your baby during this time.

    Relate drugs

    How to use Alectinib

  • The recommended dose of alectinib is 600 mg orally twice daily. Administer alectinib with food.
  • See full prescribing information for further information about dosing.

    • Warnings

    Alectinib may cause serious side effects, including:

  • Liver problems (hepatotoxicity). Alectinib may cause liver injury. Your healthcare provider will do blood tests at least every 2 weeks for the first 3 months, and then 1 time each month and as needed during treatment with alectinib. Tell your healthcare provider right away if you get any of the following signs and symptoms:
  • feeling tired
  • feeling less hungry than usual
  • yellowing of your skin or the whites of your eyes
  • dark urine
  • itchy skin
  • nausea or vomiting
  • pain on the right side of your stomach area
  • bleeding or bruising more easily than normal
  • Lung problems. Alectinib may cause severe or life-threatening swelling (inflammation) of the lungs during treatment. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening symptoms, including trouble breathing, shortness of breath, cough, or fever.
  • Kidney problems. Alectinib may cause severe or life-threatening kidney problems. Tell your healthcare provider right away if you have a change in the amount or color of your urine, or if you get new or worsening swelling in your legs or feet.
  • Slow heartbeat (bradycardia). Alectinib may cause very slow heartbeats that can be severe. Your healthcare provider will check your heart rate and blood pressure during treatment with alectinib. Tell your healthcare provider right away if you feel dizzy, lightheaded, or if you faint during treatment with alectinib. Tell your healthcare provider if you take any heart or blood pressure medicines.
  • Muscle pain, tenderness, and weakness (myalgia). Muscle problems are common with alectinib and can be severe. Your healthcare provider will do blood tests at least every 2 weeks for the first month and as needed during treatment with alectinib. Tell your healthcare provider right away if you get new or worsening signs and symptoms of muscle problems, including unexplained muscle pain or muscle pain that does not go away, tenderness, or weakness.
  • Breakdown of healthy red blood cells earlier than normal (hemolytic anemia). Hemolytic anemia can happen in some people who take alectinib. If this happens, you may not have enough healthy red blood cells. Your healthcare provider may temporarily stop alectinib and do blood tests, if needed, to check for this problem. If you develop hemolytic anemia, your healthcare provider may either restart you on alectinib at a lower dose when the hemolytic anemia goes away, or may stop your treatment with alectinib. Tell your healthcare provider right away if you experience yellow skin (jaundice), weakness or dizziness, or shortness of breath.

    • See "What are the side effects of alectinib?" below for more information about side effects.

    What other drugs will affect Alectinib

    Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, or herbal supplements.

    Popular FAQ

    Alecensa (alectinib) is a tyrosine kinase inhibitor (TKI) that works specifically on a protein called anaplastic lymphoma kinase (ALK protein). Tyrosine kinases (TK) help to determine processes such as growth, differentiation, metabolism, and cell death, and are involved in signaling pathways – these are pathways that control and regulate the flow of information between cells and their outside environment. Research has linked abnormal TK activity or mutations to various cancers – one of these is non-small cell lung cancer. Anaplastic lymphoma kinase (ALK) mutations are present in approximately 5% of NSCLC cases, and by inhibiting this protein, Alecensa reduces the growth of ALK-positive metastatic NSCLC. Alecensa is only used in metastatic NSCLC that has been tested and confirmed to be ALK-positive. Continue reading

    Alecensa (alectinib) is a tyrosine kinase inhibitor (TKI) that works specifically on a protein called anaplastic lymphoma kinase (ALK protein). Tyrosine kinases (TK) help to determine processes such as growth, differentiation, metabolism, and cell death, and are involved in signaling pathways – these are pathways that control and regulate the flow of information between cells and their outside environment. Research has linked abnormal TK activity or mutations to various cancers – one of these is non-small cell lung cancer. Anaplastic lymphoma kinase (ALK) mutations are present in approximately 5% of NSCLC cases, and by inhibiting this protein, Alecensa reduces the growth of ALK-positive metastatic NSCLC. Alecensa is only used in metastatic NSCLC that has been tested and confirmed to be ALK-positive. Continue reading

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords